Xeris Biopharma Holdings, Inc.
News
(2)April 2026
XERS posts 2024 revenue of $217 million, maintains $201M cash reserves
# 🧾 What This Document Is This is the 2025 Annual Report (Form 10-K) for Xeris Biopharma. Think of it as the company's official, comprehensive report card for the entire year. It’s filed with the SEC and is packed with detailed information about the business, its financial results, the risks it fac
XERS Sets 2026 Annual Meeting to Vote on Directors and Executive Pay
# 🧾 What This Document Is — Your Invitation to a Company Vote This is a **proxy statement** (Form DEF 14A) for Xeris Biopharma. Think of it as an official invitation and handbook for the company's annual meeting. Its job is to give shareholders the information they need to vote on important compan
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.